Dr. Sanjay Verma, MD FACC, brilliant, one of the true warrior doctors: "Myocarditis after COVID-19 Vaccination, The Stupefying and Humbling True Magnitude"; lost to follow-up is key; DAMAR HAMLIN

by Paul Alexander

This is excellent scholarship by Dr. Verma and must be supported. Brilliant, balanced, and with top cardiologists such as Dr. Ramin Oskoui, Dr. Peter McCullough etc., they offer the best sign post out

See this excellent paragraph from Dr. Verma, containing more information than I have heard on this issue and helps add dimensions to the questions surrounding the tragic cardiac arrest of DAMAR HAMLIN.


‘Vaccine associated myocarditis occurs with far greater incidence than CDC estimates (3–4x more than CDC estimates) as demonstrated on repeated international studies. Prognosis is also far worse than CDC estimates (many are lost to follow-up, many still have activity restrictions and have not returned to normal 3–6 months later). Those who are lost to follow-up (>40%) may have died and CDC is not releasing autopsy reports nor explaining how someone can be “lost to follow-up” in a situation where VASERS report requires CDC to follow-up on outcomes. Vaccine associated myocarditis studies by definition exclude those who may have “suddenly died” and not reached the hospital. A recent autopsy study from Germany indicates 4 of 25 (16%) of those who “died suddenly” within 20 days of recent vaccination had myocarditis from the vaccination (with other causes of death ruled out).’


Also this informative piece:



‘During the past 2.5 years of the COVID-19 pandemic, both SARS-CoV2 infection and COVID-19 mRNA vaccines have been associated with myocarditis. Knowing the spike protein’s affinity to ACE2 receptors in the heart and spike protein’s injury to cardiomyocytes (cells of the heart), the association of myocarditis with SARS-CoV2 virus or spike protein-based mRNA vaccination was not unexpected. Initial reports from Israel of myocarditis after vaccination surfaced in April 2021. Public Health officials in US have continued to insist that myocarditis after SARS-CoV2 infection also occurs. They emphasize CDC’s analysis which erroneously concludes risk of myocarditis after SARS-CoV2 infection is greater than after mRNA COVID-19 vaccination. Currently, over 50,000 cases of myocarditis, pericarditis, or both are reported in VAERS. As the discussion below will demonstrate, the actual number of myocarditis cases may be 3–4 times greater than reported in VAERS and the rate after vaccination is greater than after COVID-19 infection.’


‘CDC’s analysis of Vaccine Associated Myocarditis (VAM) has been and repeatedly fatally flawed. CDC continues to use VAERS data alone in most of their meeting presentations despite prior studies demonstrating that VAERS underestimates the risk of myocarditis after vaccination by 3–4 times (when compared to insurance claims data or electronic health records (EHR) databases from hospitals. In another study comparing two methodologies even found that the CDC’s method of VSD analysis under estimated the risk of VAM. The FDA Summary Basis of Regulatory Action noted that the rate of VAM in VAERS was 40 cases per million doses, “while an FDA meta-analysis of four healthcare claims databases in CBER’s Biologics Effectiveness and Safety System estimated a rate of 148 cases per 1 million males 18 to 25 years of age vaccinated with the 2-dose primary series” (3.7 times greater than the rate determined from VAERS alone). For the cases of myocarditis after SARS-CoV2 infection, CDC uses officially confirmed PCR+ ‘cases’ (for the denominator), even though their own seroprevalence data demonstrates that far more people have been infected than officially conformed PCR+ ‘cases’. For example, seroprevalence data as of Feb 21, 2022 reveal 75% (about 54 million) of all children have been infected compared to 12 million officially confirmed PCR+ ‘cases’ (i.e., the actual number of kids infected is 4.5 times greater than PCR+ ‘cases’). Therefore, calculating the risk of myocarditis after SARS-CoV2 infection, the rate noted by CDC would need to be reduced by approximately 4.5 times for pediatric population. Thus far, CDC has not adjusted its COVID-19 morbidity and mortality data accordingly. CDC’s perfunctory refrain that most cases of VAM were “generally mild” based upon follow-up on VAM reports in VAERS will be critiqued separately (forthcoming) but has been briefly reviewed at the end of my previous publication.’